Rhythm Pharmaceuticals, Inc. (RYTM) Friday said it expects full-year product revenue of about $130 million, higher than $77.4 million reported in the previous year.
For the fourth quarter, the company sees revenues from sales of IMCIVREE (setmelanotide) to be approximately $42 million, 26 percent higher than the previous quarter.
The company also added that it is on track to report topline data from the pivotal Phase 3 trial evaluating setmelanotide in acquired Hypothalamic Obesity (HO) in the first half of 2025.
The company plans to report its fourth quarter results in late February.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.